Tarpon Springs, Florida Wednesday, June 4, 2025, 12:00 Hrs [IST] ...

Therapeutics announced that the first patient has been enrolled in its new Phase 2 clinical trial protocol of stenoparib for the ...

June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...

Stenoparib, a novel dual PARP and tankyrase inhibitor, may offer a more favorable tolerability profile while providing additional therapeutic advantages. Its inhibition of PARP prevents DNA repair ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Allarity Therapeutics, Inc. announced that it has enrolled the first patient in a new Phase 2 clinical trial for stenoparib, a dual PARP and WNT pathway inhibitor, aimed at treating advanced ...

Allarity Therapeutics, Inc. has announced a research collaboration with the Indiana Biosciences Research Institute (IBRI) to enhance their understanding of stenoparib, a dual PARP and WNT pathway ...

Boston (March 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...

June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...

TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a ...